filibuvir (PF-00868554) / Pfizer - LARVOL DELTA

Inhibition of hepatitis E virus replication by FDA-Approved RdRp inhibitors (APASL 2024) - "In this study, we screened some well-known RdRp inhibitor molecules, notably, favipiravir, sofosbuvir, remdesivir, filibuvir, and tegobuvir. Therefore, favipiravir has an additive effect when used with sofosbuvir. Therefore, we propose that favipiravir is a promising anti-HEV drug that can be used in combination with sofosbuvir."

Hepatology • Inflammation

Inhibition of HEV Replication by FDA-Approved RdRp Inhibitors. (PubMed, ACS Omega) - "In this study, we screened some well-known RdRp inhibitor molecules, notably, favipiravir, sofosbuvir, remdesivir, filibuvir, and tegobuvir. Therefore, favipiravir has an additive effect when used with sofosbuvir. Therefore, we propose that favipiravir is a promising anti-HEV drug that can be used in combination with sofosbuvir."

FDA event • Journal • Hepatology • Inflammation

Drug interaction study of filibuvir with methadone, among subjects on chronic methadone maintenance -

P1, N=12; Not yet recruiting;

Hepatitis C Virus

Highly efficient infectious cell culture of three HCV genotype 2b strains and sensitivity to lead protease, NS5A, and polymerase inhibitors (Hepatology) - PMID: 23913364; "NS5B inhibitors Sofosbuvir, Mericitabine, and BI207127 had activity against 1a (strain TN), 2a...and the 2b strains, whereas VX-222 and Filibuvir only inhibited 1a. Genotype 2b strains were least sensitive to seven lead protease inhibitors, including MK-5172....NS5A inhibitor Daclatasvir was exceptionally potent, but efficacy was affected by the HCV strain."

Preclinical • Hepatitis C Virus

Filibuvir in treatment naive hepatitis C virus (HCV) genotype 1 subjects (FITNESS) (clinicaltrials.gov) - P2, N=288; Recruiting -> Completed

Trial completion • Hepatitis C Virus

Pfizer stops developing hepatitis C drug, cites strategic review (Fox Business) - "Pfizer Inc. (PFE) has stopped development of an experimental hepatitis C drug...PF-00868554, also known as filibuvir, following a strategic review... the decision wasn't related to any safety issues."

Discontinued • Hepatitis C Virus

ENCORE-LF: Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis (clinicaltrials.gov) - P2; N=210; Active, not recruiting; Sponsor: Conatus Pharmaceuticals Inc.; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed